Stockscreener 앱 받기
54.07
5.24%
-2.99
시간 외 거래:
53.41
-0.66
-1.22%
Tempus Ai Inc 주식(TEM)의 최신 뉴스
Jim Cramer Warns on Tempus AI (TEM): “Diagnostics With no Dough? I’m Out” - Insider Monkey
AI Healthcare Boom Gains Speed as Regulators and Innovators Align - The Globe and Mail
AI Healthcare Boom Gains Speed as Regulators and Innovators Align - Benzinga
Tempus Announces Notetaker, its AI-Powered Clinical Assistant for Psychiatry - Business Wire
Tempus exec-founded Pathos AI launched a $400M funding round. It's already filling up. - Crain's Chicago Business
Pathos AI gets AstraZeneca funding as biotech plans to raise up to $400M - Endpoints News
Think It's Too Late to Buy Tempus AI? Here's the Biggest Reason Why There's Still Time. - Yahoo Finance
AI-Powered Imaging Diagnostics Market: Growth, Trends & - openPR.com
Tempus selects TIME Network for Phase I clinical trials - Yahoo Finance
Tempus TIME Network Expands Support of Phase I Clinical Trials To Accelerate Activation and Enrollment - Yahoo Finance
Is This the Best Nancy Pelosi Stock to Buy After a 40% Pullback? - The Globe and Mail
Tempus AI publishes xF+ assay study results in Journal of Molecular Diagnostics - TipRanks
Tempus Publishes Study Validating the Benefits of xF+, its Comprehensive Liquid Biopsy Assay for Therapy Selection - The Joplin Globe
Tempus AI Stock Surges 43% in Q1: Buy Now or Wait for Earnings? - MSN
Press Release Service: Tempus Introduces Loop, an AI-Powered Target Discovery and Validation Platform - CRISPR Medicine News
8 Top Nancy Pelosi Stocks to Buy - US News Money
tempus AI Inc Class A call volume above normal and directionally bullish - TipRanks
Tempus AI Announces 18 Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025 - marketscreener.com
Analysts Split on High-Stakes ‘Call Option’ for Tempus AI Stock (TEM) - TipRanks
Tempus AI introduces Loop for accelerated cancer target discovery - Investing.com
Tempus AI introduces Loop for accelerated cancer target discovery By Investing.com - Investing.com UK
Tempus Introduces Loop, an AI-Powered Target Discovery and Validation Platform - Business Wire
Why Tempus AI Inc. (TEM) Soared Last Week - Insider Monkey
Tempus Announces 18 Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025 - 01net
Tempus AI Stock (TEM) Surges over 14% in a Day – What’s Next for Investors? - The Globe and Mail
The Zacks Analyst Blog Highlights Tempus AI, AstraZeneca, iRhythm Technologies and SOPHiA GENETICS - Yahoo Finance
Tempus AI to Report First Quarter 2025 Financial Results on May 6 - marketscreener.com
Tempus AI Stock Sees 21% Gain in 3 Days: Is it a Buy After AZN Deal? - MSN
Avidicure’s $50M seed round; Flagship’s new AI company that detects disease - Endpoints News
Tempus to Report First Quarter 2025 Financial Results on May 6 - Business Wire
Beyond The Numbers: 9 Analysts Discuss Tempus AI Stock - Benzinga
AstraZeneca enters $200m AI cancer pact with Tempus and Pathos - Pharmaceutical Technology
AstraZeneca joins Tempus, Pathos in cancer AI project - Pharmaphorum
Tempus partners with AstraZeneca and Pathos for oncology AI model - World Pharmaceutical Frontiers
These 10 Firms Topped Wednesday’s Trading - Insider Monkey
Tempus AI, Inc. (TEM): A Bull Case Theory - MSN
Why Tempus AI Inc. (TEM) Went Up On Wednesday - Insider Monkey
Tempus AI shares surge on new oncology partnerships By Investing.com - Investing.com India
Tempus AI shares surge on new oncology partnerships - Investing.com
Tempus expands partnership with AstraZeneca to build oncology model - MSN
AstraZeneca joins three-way $200M AI oncology deal - FirstWord Pharma
Tempus AI jumps after multi-year deals with AstraZeneca, Pathos AI - TradingView
Why Tempus AI Stock Is Skyrocketing Today - MSN
Tempus AI Is Skyrocketing Today -- Is the Stock a Buy Right Now? - MSN
Is Tempus AI, Inc. (TEM) the Best Nancy Pelosi Stock To Invest In Now? - Insider Monkey
0.10%
1.46%
자본화:
|
볼륨(24시간):